A number of other equities analysts have also recently issued reports on GMDA. Zacks Investment Research upgraded Gamida Cell from a hold rating to a buy rating and set a $15.00 price objective for the company in a report on Friday, March 1st. Oppenheimer set a $20.00 price objective on Gamida Cell and gave the company a buy rating in a report on Tuesday, February 26th. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The stock presently has an average rating of Buy and a consensus price target of $18.67.
Shares of NASDAQ:GMDA traded up $0.20 during trading hours on Wednesday, hitting $7.95. 4,607 shares of the company’s stock traded hands, compared to its average volume of 17,205. Gamida Cell has a 1 year low of $6.65 and a 1 year high of $15.41. The firm has a market capitalization of $192.57 million and a PE ratio of -0.75.
Institutional investors have recently added to or reduced their stakes in the business. Norges Bank purchased a new stake in Gamida Cell in the 4th quarter valued at about $88,000. Millennium Management LLC purchased a new stake in Gamida Cell in the 4th quarter valued at about $210,000. Delek Group Ltd. purchased a new stake in shares of Gamida Cell in the fourth quarter valued at approximately $298,000. Finally, FMR LLC purchased a new stake in shares of Gamida Cell in the fourth quarter valued at approximately $1,243,000. 1.76% of the stock is owned by institutional investors.
About Gamida Cell
Gamida Cell Ltd. is a clinical stage biopharmaceutical company, which engages in the development of cell therapies that are designed to cure cancer and rare serious hematologic diseases. Its products pipeline include NiCord and NAM-NK. The company was founded by Tony Peled and Menashe Levy in 1998 and is headquartered in Jerusalem, Israel.
Further Reading: Trading based on a resistance level
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Gamida Cell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gamida Cell and related companies with MarketBeat.com's FREE daily email newsletter.